Savvy Updates 7/22/24: ALERT: Dexcom G7 & Geofencing, Sensulin Glucose-Responsive Insulin, Bulsai Infrared Sensor for Placing for Insulin Injections, iAPS/Trio DIY Insulin Algorithm, Replica Health Personalized Metabolic Healthcare, Free Lifetime US National Parks Pass

Savvy Updates 7/22/24: ALERT: Dexcom G7 & Geofencing, Sensulin Glucose-Responsive Insulin, Bulsai Infrared Sensor for Placing for Insulin Injections, iAPS/Trio DIY Insulin Algorithm, Replica Health Personalized Metabolic Healthcare, Free Lifetime US National Parks Pass

Dexcom G7 & Geofencing: Travel Alert If you are a Dexcom G7 user or using MDI with connection to phone app, PLEASE READ: you are planning travel shortly away from your home country, and you use open-source DIY app or MDI or Mobi or will use O5 with G7 Dexcom G7 is...
Savvy Updates 7/15/24:  Novo Icodec Rejected by FDA, Is Stevia Safe?, Sucrolose & Environment, BG Changes Impact Cognitive Function, Ypsomed Pump, Islet Cell Replacement Therapy, FTC to Sue 3 Largest PBMs, GO-Pen Creates Equal Access, Medicare Cuts Physician Pay

Savvy Updates 7/15/24: Novo Icodec Rejected by FDA, Is Stevia Safe?, Sucrolose & Environment, BG Changes Impact Cognitive Function, Ypsomed Pump, Islet Cell Replacement Therapy, FTC to Sue 3 Largest PBMs, GO-Pen Creates Equal Access, Medicare Cuts Physician Pay

Novo’s once-weekly insulin rejected by FDA by Kristin Jensen for BioPharmaDive.com, 11 July 2024. Novo is one of the world’s premier manufacturers, along with Indianapolis-based Eli Lilly. Both have been working for years to offer patients a more convenient option...
Savvy Updates, 5/28/24: CamDiab Hybrid Closed Loop Approved, FDA Rejects Icodec, Ozempic Protects Kidneys, GLP-1 OK for Surgery, Physician Compensation Report 2024, Novo Nordisk Fires, Think Like a Pancreas: Is there a conspiracy?, Air Protein Solein, FIX Prior Authorizations

Savvy Updates, 5/28/24: CamDiab Hybrid Closed Loop Approved, FDA Rejects Icodec, Ozempic Protects Kidneys, GLP-1 OK for Surgery, Physician Compensation Report 2024, Novo Nordisk Fires, Think Like a Pancreas: Is there a conspiracy?, Air Protein Solein, FIX Prior Authorizations

FDA approves hybrid closed-loop insulin delivery app from CamDiab by Sean Whooley for DrugDelieveryBusiness.com, 24 May 2024. CamDiab announced today that the FDA granted authorization for its CamAPS FX advanced adaptive closed-loop artificial pancreas app. CamAPS FX,...
Savvy Updates 5/20/24: Twiist Insulin Pump, FDA Alerts on Chinese Syringe Imports, Playing Sports Lowers Insulin Resistance, Insulin Sensitizers, Dr. Rayhan Lal on Automated Insulin Delivery Systems, ADA Lists Best Hospitals for T1Ds (ONLY 17 in the US!), CGMs & Insulin Pumps for T2D Market, Black Basta Cyberattacks on Healthcare Systems, Prior Auths Need to be Fixed

Savvy Updates 5/20/24: Twiist Insulin Pump, FDA Alerts on Chinese Syringe Imports, Playing Sports Lowers Insulin Resistance, Insulin Sensitizers, Dr. Rayhan Lal on Automated Insulin Delivery Systems, ADA Lists Best Hospitals for T1Ds (ONLY 17 in the US!), CGMs & Insulin Pumps for T2D Market, Black Basta Cyberattacks on Healthcare Systems, Prior Auths Need to be Fixed

Meet the newest insulin pump: all about “twiist” with Sequel CEO Alan Lotvin by Stacey Simms for Diabetes-Connections.com, 16 April 2024. This week, the newest pump coming to the market is called the twiist. It’s a very different shape – circular with a top half that...
Savvy Updates, 4/29/24:  Cadisegliatin Regulates BG in Liver, Diabetes Driving Pal App, Female Physicians Result in Better Health Outcomes, UHC Data Breach “Substantial”, Pancreas Anatomy Image, Little Sleep Risky for T1D Teens, Vertex/TreeFrog Collab, Mounjaro/Zepbound Shortages, Ozempic in Denmark, Roasted Green Tea (houjicha)

Savvy Updates, 4/29/24: Cadisegliatin Regulates BG in Liver, Diabetes Driving Pal App, Female Physicians Result in Better Health Outcomes, UHC Data Breach “Substantial”, Pancreas Anatomy Image, Little Sleep Risky for T1D Teens, Vertex/TreeFrog Collab, Mounjaro/Zepbound Shortages, Ozempic in Denmark, Roasted Green Tea (houjicha)

Introducing Cadisegliatin, a New Drug in the Type 1 Diabetes Pipeline by Ross Wollen for DiabetesDaily.com, 26 April 2024. Cadisegliatin, an investigative therapy currently entering phase 3 trials, could be the next important drug, after insulin, indicated for Type 1...
Skip to content